Effect of Bezafibrate on Soluble Adhesion Molecules and Platelet Activation Markers in Patients With Connective Tissue Diseases and Secondary Hyperlipidemia

Abstract

We evaluated the plasma concentrations of soluble adhesion molecules, platelet activation markers, and platelet-derived microparticles (PMPs) in patients with connective tissue diseases who had secondary hyperlipidemia caused by long-term steroid administration (n = 22) before and after treatment with bezafibrate. There were differences in levels of platelet. activation markers both before and after treatment (platelet CD62p: 15.11 ± 2.03 vs 10.38 ± 8.53%. P < 0.05; ptatetet CD63: t2.i2 ± 9.17 vs 9.90 ± 7.20%, P < 0.05). There were also differences in the levels of PMPs and soluble adheSion molecules both before and after treatment (PMP: 514 ± 273 vs 401 ± 201 /104 platelet, P < 0.05; soluble vascular cell adhesion molecule-1 : 724 ± 191 vs 666 ± 157 ng/mL, P < 0.01). After 6 months of treatment, serum lipid concentrations were reduced by 9% for total cholesterol (TC) and 32% for triglyceride (TG). The level of PMPs, activated platelets, and soluble adhesion molecules were all significantly decreased after treatment with bezafibrate. These findings suggest that bezafibrate may be useful for inhibiting both PMP-dependent and -independent vascular damage in patients with connective tissue diseases complaining of secondary hyperlipidemia.

Keywords

Bezafibrate Connective tissue diseases Platelet-derived microparticle Secondary hyperlipidemia Soluble adhesion molecule.

References

Lin RC , Snodgrass PJ Effect of dexamathasone on 3-hydroxy 3-methyl glutaryl Coenzyme A reductase activity and cholesterol synthesis in rat liver. Biochim Biophys Acta 1982;713:240.

Stern MP , Kolterman OG , Fries JF , et al. Adrenocortical steroid treatment of rheumatic disease. Arch Int Med 1973; 132:97.

Koizumi F. , Fukase M. , Wakaki K. Clinicopathological study of coronary arterial lesions in 60 cases with systemic lupus erythematosus. Clin Immunol 1982;14:406.

Kagawa H. Okubo S. Yasunaga K. Plasma coagulation and fibrinolysis parameters in patients with collagen diseases, and analysis of the multimeric structure of von Willebrand factor (vWF). Int J Hematol 1991;54:429.

Angles-Cano E. , Sultan Y. , Cluvel J-P. Predisposing factors to thrombosis in systemic lupus erythematosus. Arthritis Rheum 1982 25:1271.

Rick ME , Hoyer LW Haemostatic disorders in systemic lupus erythematosus. Clin Rheum Dis 1982;1:583.

Kahaleh MB Osborn I. , Leroy EC Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scteroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94: 482.

Murakami T. , Komiyama Y. , Masuda M. , et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. Eur J Clin Invest 1996;26:996.

Sims PJ , Wiedmer T. , Esmon CT , et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem 1989;264:17049.

10.

Nomura S. , Komiyama Y. , Matsuura E. et al. Participation of α 11b β3 in platelet microparticle generation by collagen plus thrombin. Haemostasis 1996;26:31.

11.

Springer TA Adhesion receptors of the immune system. Nature 1990:346:425.

12.

Bevilacqua MP Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993;1:767.

13.

Kling E. , Bieg S. , Boehme M. , et al. Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. J Clin Invest 1993;71:299.

14.

Sfikakis PP , Charalambopoulos D. , Vayioppulos G. , et al. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12:5.

15.

Janssen BA , Luqmani RA , Gordon C. , et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis . Br J Rheumatol 1994;33:1112.

16.

Miettinen T. Cholesterol balance and lipoprotein metabolism in man. Atheroscler Rev 1986; 15: 113.

17.

Elinarsson K. , Angelin B. Hyperlipoproteinemia, hypolipidemic treatment and gallstones disease. Atheroscler Rev 1986 ;15:67.

18.

Eisenberg S. , Gavish D. , Oschry Y. , et al. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafthrate treatment. J Clin Invest 1984;74: 470.

19.

Sullivan DR , Ktuijswijk Z. West CE , et al. Determination of serum triglyceride by an accurate enzymatic method not affected by free glycerol. Clin Chem 1985;31:1227.

20.

Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chein 1973;19:1350.

21.

Miyazaki Y. , Nomura S. , Miyake T. , et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996;88:3456.

22.

Nomura S. , Suzuki M. , Katsura K. , et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995; 116:235.

23.

Miyake T. , Nomura S. , Komiyama Y. et al. Effect of a new monoclonal anti-glycoprotein IX antibody, KMP-9, on high shear-induced platelet aggregation. Thromb Haemost 1997;78:902.

24.

Nomura S. , Nagata H. , Oda K. , et al. Effects of EDTA on membrane glycoprotein IIb-IIIa complex: analysis using flow cytometry. Thromb Res 1987;47:47.

25.

Yanabu M. , Ozaki Y. , Nomura S. , et al. Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monaclonal antibody. Blood 1997;89:1590.

26.

Chobanian AV Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hyper hypercholesterolemia coexist. Hypertension 1991;18:130.

27.

Gearing Ajh , Newman W. Circulating adhesion molecules in disease . Immunol Today 1993; 14:506.

28.

Sims PJ , Wiedmer T. , Esmon CT , et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem 1989;264:17049.

29.

Zwaal Rfa , Comfurius P. , Bevers EM Platelet procoagulant activity and microvesicle formation: its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180: 1.

30.

Tans G. , Rosing J. , Thomassen MC , et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticle'.s. Blood 1991-177:2641.

31.

Dahlback B. , Wiedmer T. , Sims PJ Binding of anticoagulant vitamin K-dependent protein S to platelet-derived micropartictes. Biochemistry 1992,31:12769.

32.

Gilbert GE , Sims PJ , Wiedmer T. , et al. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991;266:17261 .

33.

Comfurius P. , Senden Jmg , Tilly Rhj , et al. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of amminophosphotipid translocase . Biochim Biophys Acta 1990;1026:153.

34.

Jy W. , Horstmann LL , Arce M. , et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119:334.

35.

Hailer S. , Pogarell O. , Keller C. , et al. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypcrchoiesterotemia . Arzneimittelforschung 1996;46:879.

36.

Spieker LE , Noll G. , Hannak M. , et al. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharmacol 2000;35:361.

37.

Barry OP , Pratico D. , Lawson JA , et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997;99:2118.